Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $77.61 USD
Change Today -0.89 / -1.13%
Volume 4.7M
MDT On Other Exchanges
Symbol
Exchange
Mexico
Frankfurt
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

medtronic plc (MDT) Snapshot

Open
$78.48
Previous Close
$78.50
Day High
$78.48
Day Low
$77.58
52 Week High
03/25/15 - $79.50
52 Week Low
04/28/14 - $58.00
Market Cap
110.6B
Average Volume 10 Days
4.6M
EPS TTM
$4.00
Shares Outstanding
1.4B
EX-Date
03/26/15
P/E TM
19.4x
Dividend
$1.22
Dividend Yield
1.57%
Current Stock Chart for MEDTRONIC PLC (MDT)

medtronic plc (MDT) Details

Medtronic plc, a healthcare solutions company, provides medical technologies, services, and solutions worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group’s products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management devices; products to reduce surgical site infections; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; and systems that incorporate advanced energy surgical instruments. It also manufactures and sells image-guided surgery and intra-operative imaging systems. The Diabetes Group’s products include insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. The company also offers a portfolio of surgical, respiratory and monitoring, and vascular therapies solutions, as well as medical supplies. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.

49,247 Employees
Last Reported Date: 11/21/14
Founded in 1949

medtronic plc (MDT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $774.9K
Executive Vice President and Group President ...
Total Annual Compensation: $724.9K
Executive Vice President and Group President ...
Total Annual Compensation: $675.1K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2014.

medtronic plc (MDT) Key Developments

Medtronic Announces European Approval of the First and Only Full-Body MR Conditional Deep Brain Stimulation Systems

Medtronic plc announced that systems within its Activa portfolio of Deep Brain Stimulation (DBS) Therapy neurostimulators have received European regulatory approval for MR Conditional full-body Magnetic Resonance Imaging (MRI). The expanded approval for full-body MRI scans applies to all patients receiving a new system and to an estimated 13,000 people in Europe already receiving Medtronic DBS Therapy. Medtronic DBS systems have previously been approved for MRI scans of the head only, under limited conditions. Medtronic DBS systems are not approved in the United States for full-body scans. To receive approval for MR Conditional DBS systems, Medtronic developed proprietary test and measurement systems, in conjunction with advanced electromagnetic modeling tools. Existing Activa DBS systems were rigorously tested and evaluated across millions of simulated patient scans spanning over 38,000 unique implant conditions to demonstrate patient safety.

International Business Machines Corporation and Medtronic plc Partner to Develop Next Generation Diabetes Management Solutions

International Business Machines Corporation and Medtronic plc have partnered to develop next generation diabetes management solutions by combining analytics and cognitive computing with diabetes medical devices and health data. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit. IBM and Medtronic are exploring ways to develop diabetes care management solutions that will optimize patient outcomes and health economics, leveraging Medtronic's devices and care management offerings, including therapies and coaching, and IBM's Watson Health Cloud platform. In addition, the two companies also expect to develop near real-time, dynamic care plans that provide decision support for health care providers and their patients with the goal of improving care efficiency and outcomes. IBM and Medtronic will also jointly explore ways to leverage IBM's Watson platform to improve Medtronic and partners' closed loop algorithms, which intend to mimic the function of a healthy pancreas.

Medtronic plc to Develop Stent Graft System for Repair of Aneurysms Under Agreement with Sanford Health

Medtronic plc announced that it plans to develop a stent graft system for less invasive treatment of thoracoabdominal aortic aneurysms under an exclusive patent license agreement with Sanford Health. Sanford Health holds the intellectual property covered by the exclusive patent license agreement with Medtronic. Medtronic plans to study the system in collaboration with physicians at several medical centers, including Kelly at Sanford Health, starting in the near future and subsequently to commercialize it after obtaining the required regulatory approvals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $77.61 USD -0.89

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.07 USD +1.82
Actavis plc $295.41 USD -2.95
Amgen Inc $167.91 USD -1.26
Biogen Inc $401.71 USD -28.57
Bristol-Myers Squibb Co $65.80 USD -0.20
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 24.9x
Price/Sales 4.4x
Price/Book 3.8x
Price/Cash Flow 31.8x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC PLC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.